Search results
Results from the WOW.Com Content Network
A royalty payment is a payment made by one party to another that owns a particular asset, for the right to ongoing use of that asset. Royalties are typically agreed upon as a percentage of gross or net revenues derived from the use of an asset or a fixed price per unit sold of an item of such, but there are also other modes and metrics of compensation.
Patent monetization refers to the generation of revenue or the attempt to generate revenue by a person or company by selling or licensing the patents it owns.. Some of these owners try to make money from patents on inventions they develop, manufacture or market.
Royalty payments take three basic forms: 'running' royalties 'lumpsum' royalty; running royalties together with lump-sum royalties; Any payment should be related to: the specific entity of the license that bears the royalty; the unit-base on which the royalty is applicable (e.g. per kilogram of product) the period over which payments are due
Patent licensing agreements are contracts in which the patent owner (the licensor) agrees to grant the licensee the right to make, use, sell, or import the claimed invention, usually in return for a royalty or other compensation.
The term "cross licensing" implies that neither party pays monetary royalties to the other party, although this may be the case. For example, Microsoft and JVC entered into a cross license agreement in January 2008. [3] Each party, therefore, is able to practice the inventions covered by the patents included in the agreement. [4]
The Federal Trade Commission is mailing more than 17,000 checks to amateur inventors swindled by an official-sounding group of promoters that promised to evaluate their ideas and help them strike ...
In the field of intellectual property licensing, an advance against royalties is a payment made by the licensee to the licensor at the start of the period of licensing (usually immediately upon contract, or on delivery of the property being licensed) which is to be offset against future royalty payments.
the patented invention is not available to the public at a reasonably affordable price, or, the patented invention is not worked [25] in the territory of India. In March 2012, India granted its first compulsory license ever to Indian generic drug manufacturer Natco Pharma for Sorafenib tosylate, a cancer drug patented by Bayer. [26]